Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer

Bibliography

• EASTHAM JA, SCARDINO PT: Radical prostatectomy for clinical stage Ti and T2 prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology Vogelzang NJ, Scardino PT, Shipley WU et al. (Eds), Lippincott Williams & Wilkins, Baltimore, MA, USA (2000):722–738.
   Google Scholar
• GROSSFELD GD, CHANG JJ, BROERING JM et al: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. Urol. (2001) 165(3):851–856.
   Web of Science ®Google Scholar
• EASTHAM JA, RIEDEL E, SCARDINO PT et al.: Variation of serum prostate specific antigen levels: an evaluation of year-to-year fluctuations in a well defined cohort of men. JAMA (2003) 289(20):2695–2700.
   PubMed Web of Science ®Google Scholar
• PARTIN AW, KATTAN MW, SUBONG EN et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localised prostate cancer. A multi-institutional update. JAMA (1997) 277(18):1445–1451.
   Google Scholar
• ROACH M 3rd, MARQUEZ C, YUO HS et al.: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localised prostate cancer. Int. I Radial-. Oncol Biol. Phys. (1994) 28(1):33–37.
   Google Scholar
• KATTAN MW, EASTHAM JA, STAPLETON AM, WHEELER TM, SCARDINO PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. (1998) 90(10):766–771.
   PubMed Web of Science ®Google Scholar
• ••Discusses the concept of nomograms andtheir use in identifying patients at high risk for failure after radical prostatectomy.
   Google Scholar
• GRAEFEN M, KARAKIEWICZ PI, CAGIANNOS I et al.: International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy.Oncol (2002) 20(15):3206–3612.
   Google Scholar
• BIANCO F Jr, KATTAN MW, SCARDINO PT, POWELL IJ, PONTES EJ, WOOD, DP Jr: Radical prostatectomy nomograms in black American men: accuracy and applicability. Urol. (2003) 170(1):73–76.
   Web of Science ®Google Scholar
• KATTAN MW, SHARIAT SF, ANDREWS B, ZHU K, MATSUMOTO K, SLAWIN K: The addition of interleukin-6 soluble receptor and transforming growth factor B-1 improves a pretreatment nomogram for predicting recurrence in patients with clinically localised prostate cancer. J. Clin. Oncol (2003) 21(19):3573–3579.
   PubMed Web of Science ®Google Scholar
• GRAEFEN M, KARAKIEWICZ PI, CAGIANNOS I et a/.: A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol. Oncol (2002) 7(4):141–146.
   Google Scholar
• KATTAN MW, ZELEFSKY MJ, KUPELIAN PA, SCARDINO PT, FUKS Z, LIEBEL SA: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer." Clin. Oncol (2000) 18:3352–3359.
   PubMed Web of Science ®Google Scholar
• KATTAN MW, POTTERS L, BLASKO JC et al.: Pretreatment nomogram for predicting freedom from recurrence after permanent brachytherapy in prostate cancer. Urology (2000) 58:393–399.
   Web of Science ®Google Scholar
• KATTAN MW, REUTER V, MOTZER RJ, KATZ J, RUSSO P: A postoperative prognostic nomogram for renal cell carcinoma. J. Urol (2001) 166:63–67.
   PubMed Web of Science ®Google Scholar
• KATTAN MW, LEUNG DHY, BRENNAN MF: A postoperative nomogram for 12-year sarcoma-specific death. " Clin. Oncol (2002) 20:791–796.
   PubMed Web of Science ®Google Scholar
• KATTAN MW, KARPEH MS, MAZUMDAR M, BRENNAN MF: Postoperative nomogram for disease-specific survival following an RO resection for gastric carcinoma. J. Clin. Oncol (2003) 21(19):3647–3650.
   PubMed Web of Science ®Google Scholar
• KATTAN MW, SCARDINO PT: Prediction of progression: nomograms of clinical utility. Clin. Prostate Cancer (2002) 1:90–96.
   PubMedGoogle Scholar
• SYED S, PETRYLAK DP, THOMPSON IM: Management of high-risk localised prostate cancer: the integration of local and systemic therapy approaches. Urol. Omni: Seminars and Original Investigations (2003) 21:235–243.
   PubMed Web of Science ®Google Scholar
• ••Excellent overview of current conceptsregarding multimodal treatment strategies in prostate cancer.
   Google Scholar
• BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl. Med. (1997) 337(5):295–300.
   PubMed Web of Science ®Google Scholar
• ABBAS F, SCARDINO PT: Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol. Clin. North Ain (1996) 23:587–604.
   PubMed Web of Science ®Google Scholar
• VAN POPPEL H, AMEYE F, OYEN R et al.: Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy. Acta. Urol. Belg. (1992) 60:73–82.
   PubMedGoogle Scholar
• RABBANI F, BASTAR A, FAIR WR: Neoadjuvant hormone therapy before radical prostatectomy: update on Phase II and III Memorial Sloan-Kettering Cancer Center trials. Ma Urol. (1998) 2:151–157.
   Web of Science ®Google Scholar
• SCHELLHAMMER P, COCKETT A, BOCCON-GIBOD L et al: Assessment of endpoints for clinical trials for localised prostate cancer. Urology (1997) 49:27–38.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG SL, KLOTZ LH, SRIGLEYJ et al: Randomised, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localised prostate cancer. Canadian Urologic Oncology Group. J. Urol. (1996) 156:873–877.
   Google Scholar
• SOLOWAY MS, PAREEK K, SHARIFI R et al.: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. Urol. (2002) 167(1):112–116.
   Web of Science ®Google Scholar
• •Summary of 5-year cancer control outcomes after neoadjuvant androgen deprivation therapy and radical prostatectomy.
   Google Scholar
• FAIR WR, RABBANI F, BASTAR A, BETANCOURT J: Neoadjuvant hormone therapy before radical prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center trials. MM. Urol (1999) 3(3):253–260.
   PubMed Web of Science ®Google Scholar
• WITJES WP, SCHULMAN CC, DEBRUYNE FM: Preliminary results of a prospective randomised study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 NO MO prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology (1997) 49:65–69.
   Google Scholar
• TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. Clin. Oncol (1996) 14(6):1756–1764.
   Web of Science ®Google Scholar
• KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study." Clin. Oncol (1999) 17(8):2506–2513.
   Google Scholar
• HARTLEY-ASP B, GUNNARSSON PO: Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). Urol (1982) 127(4):818–822.
   Web of Science ®Google Scholar
• STEARNS ME, WANG M, TEW KD, BINDER LI: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J. Cell Biol. (1988) 107(6 Pt 2):2647–2656.
   Google Scholar
• EKLOV S, NILSSON S, LARSON A, BJORK P, HARTLEY-ASP B: Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells M vivo. Prostate (1992) 20(1):43–50.
   PubMed Web of Science ®Google Scholar
• SPEICHER LA, LAING N, BARONE LR, ROBBINS JD, SEAMON KB, TEW KD: Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. MM. Pharmacol (1994) 46(5):866–872.
   PubMed Web of Science ®Google Scholar
• HARTLEY-ASP B: Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate (1984) 5(1):93–100.
   PubMed Web of Science ®Google Scholar
• VAN POPPEL H, WERBROUCK PW, BAERT L: Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer. Acta. Urol. Belg (1990) 58(4):89–95.
   Google Scholar
• HUDES GR, NATHAN F, KHATER C et al.: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.j Clin. Oncol (1997) 15(9):3156–3163.
   Google Scholar
• PETRYLAK DP, MACARTHUR R O'CONNOR J et al.: Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone refractory prostate cancer. Semin. Oncol (1999) 26(5 Suppl. 17):28–33.
   Google Scholar
• SINABALDI VJ, CARDUCCI M, LAUFER M, EISENBERGER M: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin. Oncol (1999) 26(5 Suppl. 17):45–48.
   Google Scholar
• PIENTA KJ, REDMAN B, HUSSAIN M et al.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.j Clin. Oncol (1994) 12(10):2005–2012.
   Google Scholar
• KELLY WK, CURLEY T, SLOVIN S et al.: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol (2001) 19(1):44–53.
   PubMed Web of Science ®Google Scholar
• •Details outcomes using combination chemotherapy in men with hormone-refractory prostate cancer. Demonstates improved efficacy of newer chemotherapeutic agent in prostate cancer.
   Google Scholar
• PICUS J, SCHULTZ M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. (1999) 26(5 Suppl. 17):14–18.
   Google Scholar
• BEER TM, HOUGH KM, GARZOTTO M et al: Treatment of androgen-independent prostate cancer with weekly high-dose calcitriol and docetaxel. 37th Annual Meeting of the American Society of Clinical Oncology (2001). (Abstract 2369).
   Google Scholar
• BERRY W, GREGURICH M, DAKHIL S, HATHORN J, ASMAR L. Phase II randomised trial of weekly paclitaxel with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic prostate cancer. 37th Annual Meeting of the American Society of Clinical Oncology (2001). (Abstract 696).
   Google Scholar
• SAVARESE DM, HALABI S, HARS V et al.: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.,/ OM. Oncol (2001) 19(9):2509–2516.
   Google Scholar
• CLARK PE, PEEREBOOM DM, DREICER R, LEVIN HS, CLARK SB, KLEIN EA: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology (2001) 57(2):281–285.
   PubMed Web of Science ®Google Scholar
• PETTAWAY CA, PISTERS LL, TRONCOSO P et al.: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.' Clin. Oncol (2000) 18(5):1050–1057.
   Google Scholar
• KONETY BR, EASTHAM J, SCARDINO PT et al: Radical prostatectomy following neo-adjuvant chemo-hormonal therapy for high-risk or locally advanced prostate cancer: a Phase I/II study. J. Urol. (2004) (In press).
   Google Scholar
• •Detailed overview of a contemporary series of patient treated with neoadjuvant chemotherapy and radical prostatectomy.
   Google Scholar
• EASTHAM JA, KELLY WK, GROSSFELD GD, SMALL E: CALGB Trial 90203: randomised Phase III study of radical prostatectomy alone versus estramustine and docetaxel prior to radical prostatectomy for patients with high-risk localised disease. Urology (2004) (In press).
   Google Scholar
• MESSING EM, MANOLA J, SAROSDY M, WILDING G, CRAWFORD ED, TRUMP D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl. J. Med. (1999) 341(24):1781–1788.
   PubMed Web of Science ®Google Scholar
• STANFORD JL, FENG Z, HAMILTON AS et al.: Urinary and sexual function after radical prostatectomy for clinically localised prostate cancer: The Prostate Cancer Outcomes Study. JAMA (2000) 283:354–360.
   PubMed Web of Science ®Google Scholar
• MADALINSKA JB, ESSINK-BOT ML, DEKONING HJ, KIRKELS WJ, VAN DER MAAS PJ, SCHRODER FH: Health related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localised prostate cancer. J. Clin. Oncol (2001) 19:1619–1628.
   PubMed Web of Science ®Google Scholar